Quantitative Analysis of Dried Bloodspot 17-Hydroxyprogesterone by ACQUITY UPLC-MS/MS for Clinical Research

Importance of the Topic

17-Hydroxyprogesterone (17-OHP) is a critical biomarker for assessing adrenal function and monitoring congenital adrenal hyperplasia in clinical research. Traditional immunoassays for 17-OHP often suffer from cross-reactivity with structurally related steroids, leading to inaccurate results. The dried blood spot (DBS) format offers a minimally invasive sampling approach, enhanced analyte stability, and simplified logistics, making it an attractive matrix for longitudinal studies and large-scale screening programs.

Objectives and Study Overview

This work describes the development and validation of a high-throughput UPLC-MS/MS method for quantifying 17-OHP in DBS samples. Specific goals included achieving rapid analysis, improved selectivity versus immunoassay techniques, and sufficient sensitivity to capture clinically relevant concentration ranges. Additionally, qualitative evaluation of androstenedione and cortisol was integrated to verify chromatographic separation and potential interferences.

Methodology and Instrumentation

DBS samples (two 3 mm punches) were extracted by agitation in acetone/acetonitrile with an isotopically labeled 2H8-17-OHP internal standard. After evaporation and reconstitution in aqueous/organic mobile phase, 20 µL was injected onto an ACQUITY UPLC HSS T3 column. A binary gradient from 45 % to 98 % organic mobile phase provided baseline separation of 17-OHP, androstenedione, and cortisol in a 3.5-minute cycle. Electrospray positive ionization MS/MS detection employed multiple-reaction monitoring with optimized cone voltages and collision energies for each analyte.

Used Instrumentation

• ACQUITY UPLC System with HSS T3 column and VanGuard pre-column
• Xevo TQ MS triple-quadrupole mass spectrometer
• TruView Maximum Recovery vials and 96-well extraction plates
• MassLynx software with TargetLynx Application Manager

Results and Discussion

Calibration curves over 9.9–1270 nmol/L displayed excellent linearity (r2 > 0.997) and accuracy within ±10 % of nominal values. The lower limit of quantification (LLOQ) was 1.6 nmol/L (SNR > 10) and limit of detection (LOD) was 0.5 nmol/L (SNR > 3). Within- and between-batch imprecision was below 6.7 % CV across quality control levels (76–303 nmol/L). Extraction efficiency averaged 58 %, while matrix effects suppressed signal by approximately 15 %; post-column infusion confirmed no co-eluting suppressants.

Benefits and Practical Applications

• Rapid throughput with 3.5 min analysis time
• High analytical selectivity and reduced cross-reactivity
• Minimal sample volume requirements via DBS
• Robust reproducibility and sensitivity suitable for clinical research

Future Trends and Opportunities

Emerging directions include automated DBS processing, integration of full steroid panels in a single run, microfluidic sampling devices, and expansion into newborn screening workflows. Advances in high-resolution MS could further enhance specificity and enable discovery of novel biomarkers from DBS.

Conclusion

The ACQUITY UPLC-MS/MS approach delivers a fast, sensitive, and reliable method for quantifying 17-OHP in dried blood spots. Its robustness and ease of adoption make it well suited for clinical research studies requiring accurate steroid profiling.

Reference

• Wong T, et al. Identification of the steroids in neonatal plasma that interfere with 17α-hydroxy-progesterone radioimmunoassays. Clin Chem. 1992;38(9):1830–1837.